School of Medicine
Showing 1-68 of 68 Results
-
Vyas Akondi
Senior Research Scientist - Basic Life, Ophthalmology
Current Role at StanfordWe develop next-generation ocular imaging devices to allow non-invasive visualization of subcellular structures in the eye with the goal of building clinically useful tools that help in early disease diagnosis and monitoring.
-
Marco Hao Hao Ji
Visiting Instructor, Ophthalmology
BioMarco Ji is a research fellow in the Department of Ophthalmology. He completed medical school in Italy at Catholic University of Sacred Heart. He has been investigator in several translational studies as well as clinical trials. His research activities have concentrated on Retinopathy of Prematurity, Telemedicine, Fluorescein Angiography, anti-VEGFs and Deep Learning.
He has published over 20 peer-reviewed Ophthalmology journal papers and book chapters. He has served as reviewer for several scientific journals.
He is a member of the Association for Research in Vision and Ophthalmology, and the Chinese American Ophthalmological Society and the Overseas Chinese Association for Vision and Eye Research.
He is starting internship in 2020 at Icahn School of Medicine at Mount Sinai - Bronx and residency in Ophthalmology at University of Arkansas for Medical Sciences -
Stephen Smith, MD
Clinical Instructor (Affiliated) [Vapahcs], Ophthalmology
Staff, Ophthalmology Clinic and EducationCurrent Research and Scholarly InterestsRESEARCH OVERVIEW
Dr. Smith’s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.
INNOVATION HIGHLIGHTS
In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.
Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course. -
Marcus Toral
Temp - Non-Exempt, Ophthalmology
Current Role at StanfordGraduate Research Assistant
-
Gabriel Velez, PhD
Temp - TMS, Ophthalmology
Current Role at StanfordGraduate Research Assistant
